The document discusses using polyvinyl alcohol (PVA) for sustained release drug delivery formulations. It begins with an introduction that outlines the benefits of modified oral drug release and some common sustained release approaches. The main challenges with sustained release formulations are identified as dose dumping, batch-to-batch consistency, process cost efficiency, API-dependent release kinetics, and flexible modification of release profiles. Parteck SRP 80, a synthetic PVA polymer, is presented as a solution that provides consistent performance across batches and reduces processing costs through direct compression. The document demonstrates how Parteck SRP 80 can achieve sustained release of various active pharmaceutical ingredients without dose dumping, even in the presence of alcohol. The release profile can also be flexibly modified
Call Girls Secunderabad 7001305949 all area service COD available Any Time
PVA for sustained release: theory and practice
1. The life science business of Merck KGaA,
Darmstadt, Germany operates as
MilliporeSigma in the U.S. and Canada.
PVA for sustained
release: theory and
practice
Gudrun Birk
20th August 2020
2. The life science business
of Merck KGaA, Darmstadt,
Germany operates as
MilliporeSigma in the U.S.
and Canada
6. 21
Introduction
Sustained Release Approaches
Webinar - PVA for sustained release | 20.08.20206
Matrix systemsFunctional coatings
Rate controlling step: diffusion of dissolved drug through
coating; membrane-controlled
Benefits
Performance adjustable (coating type, layer thickness, pores)
‟Delayed“ release possible
Drawbacks
Additional process step costs
Batch-to-batch consistency (layer/pore homogeneity)
Risk of dose dumping
Crushing/division of tablet by patient (dose adjustment)
Gaps in coating layer
pH variability in gastrointestinal tract
Potential for alcohol-induced dose dumping
Rate controlling step: diffusion of dissolved drug through
matrix or by slow matrix erosion; matrix-controlled
Benefits
Performance adjustable (polymer type, grades thereof,
quantity)
Generally lower risk of dose dumping
Dosage forms divisible (dose adjustment)
Drawbacks
Polymers usually used are naturally derived quality and
performance variabilities
Potential for alcohol-induced dose dumping, depending on
polymer type
One single polymer does not suit all drugs
7. Introduction
Main Challenges
Webinar - PVA for sustained release | 20.08.20207
1 Dose dumping - unintended, rapid drug release in a short period of time of the entire
amount or a significant fraction of the drug contained in a modified release dosage form
2
3
4
5
Batch-to-batch consistency of formulation components
Process cost efficiency – which technology is suitable and most efficient?
API dependent release kinetics – which formulation is suitable?
Flexible modification of release profile – how can the profile adapted?
9. Parteck® SRP 80
Synthetic PVA for Sustained Release
Webinar - PVA for sustained release | 20.08.20209
2 Established solutions to-date
such as cellulose based polymers
Naturally derived products
Batch to batch consistency
Consistent quality of the excipient supports
Quality by Design and helps to minimize risks in
development and manufacture
Batch to batch variability
Challenges in formulation and production
processes
May affect release performance of final product
Inconsistent excipient quality poses a challenge
to Quality by Design implementation
Parteck® SRP 80 supports a consistent final product quality
1 Parteck® SRP 80
S(sustained) R(release) P(polyvinyl alcohol)
80(mean particle size in µm)
Fully synthetic and chemically defined product
10. Material PVA 40-88
Bulk density 0.51 - 0.58 g/ml
Tapped density 0.70 - 0.77 g/ml
Angle of repose 32°- 37°
Mean particle size (laser diffraction Dv50) 60 – 100 µm
(target ~ 80 µm)
Mean particle size (laser diffraction Dv10) 15 – 30 µm
Mean particle size (laser diffraction Dv90) 160 – 220 µm
Surface (nitrogen adsorption BET) 0.3 - 0.5 m²/g
Pore volume (nitrogen adsorption BET) not detectable
Loss on drying (3h, 105°C) ≤ 5.0%
Webinar - PVA for sustained release | 20.08.202010
Processability
Material Characteristics
Optimized particle size
for direct
compressibility
Optimized particle size
for drug dissolution
Compliant with Ph.
Eur., USP, JPE
monographs
Emprove® Program
11. Processibility
Webinar - PVA for sustained release | 20.08.202011
Amount in % (w/w)
Active ingredient 5 – 50
Parteck® SRP 80 > 20
Microcrystalline cellulose 0 - 60
Silicon dioxide, highly dispersed 0.25 – 1.50
Parteck® LUB MST 0.25 – 0.75
TOTAL 100
The Parteck® SRP 80 content of the formulation
should not be less than 20 % (w/w), otherwise
gel forming will be inhomogeneous.
Parteck® SRP 80 is designed for the formulation of sustained release oral dosage forms,
and is well suitable for direct compression processes.
General Formulation with Parteck® SRP 80
13. Cost efficiency
Direct Compression
Webinar - PVA for sustained release | 20.08.202013
1 Parteck® SRP 80
Suitable for direct compression
2 Main competitors
Typically complex, multiple-step processes
Granulation
(Dry/Wet)
Tablet
Mixing
Wetting
Granulation
Drying
Sieving
Mixing
Compression
Direct compression
Tablet
Mixing
Compression
Coating
Tablet
Coated tablet
Granulation or
direct
compression
Coating
Multiparticulates
Tablet / Capsule
Mixing
Wetting
Drying
Filling into
capsule or
tabletting
process
Extrusion
Spheronization
Substantial process cost savings through simple and economic process
14. Cost efficiency
Process Costs: Wet Granulation vs. Direct Compression
Webinar - PVA for sustained release | 20.08.202014
Wet granulation
Potential reduction of 6 additional steps
Total cost reduction up to 75%**
Compression to tablets
1. Weighing of ingredients
2. Blending of ingredients
TOTAL
Direct compression
0.4 – 1.00 €/kg
0.2 – 1.50 €/kg
0.6 – 2.50 €/kg
Process cost
(€/kg)*
1. Weighing of ingredients
2. Blending of ingredients
3. Prep. granulation fluid
4. Granulation
5. Wet sieving
6. Drying process
7. Dry sieving process
8. Add. of external phase
TOTAL
0.4 – 1.00 €/kg
0.2 – 1.50 €/kg
0.5 – 0.75 €/kg
1.0 – 2.00 €/kg
0.3 – 0.70 €/kg
1.5 – 3.00 €/kg
0.3 – 0.70 €/kg
0.3 – 0.70 €/kg
4.7 –10.35 €/kg
Process cost
(€/kg)*
*process cost was estimated based on available production data and own experience
**depending on the formulation process
Reproduced with modifications from Lammens, R. F. (2014). "Maximizing Roller Compaction
Efficiency with the Proper Excipients Selection." webinar
15. 15 Webinar - PVA for sustained release | 20.08.2020
Direct compression
Amount
[mg]
Amount
[%]
Function
Propranolol HCl 160.00 32.0 Model API
Parteck® SRP 80 335.00 67.0
Sustained
release
polymer
SiO2, highly
dispersed
2.50 0.50 Flow regulator
Parteck® LUB MST 2.50 0.50 Lubricant
Total 500.00 100
57
131
181
0
200
400
600
800
0
100
200
10 20 30
EjectionForce[N],s(rel)
TabletHardness[N],s(rel)
Compression Force [kN]
Parteck® SRP 80 example formulation,
tablet hardness [N]
Parteck® SRP 80 example formulation,
ejection force [N]
Tableting Performance
The example formulation with Parteck® SRP 80 shows high compressibility and low
ejection forces over a vast range of compression forces.
16. Direct compression
Uniformity of Tablets
Webinar - PVA for sustained release | 20.08.202016
Parameter 10 kN 20 kN 30 kN
Average
weight [mg]
498.4 499.8 500.5
Standard
deviation [mg]
4.0 2.4 2.3
1.9
1.2
1.1
0.0
0.5
1.0
1.5
2.0
10 20 30
AcceptanceValue(AV)
Compression force [kN]
SRP 80 + Propranolol x HCl
AV < 15 acc. to pharmacopoeia
AV = (M-X) + ks
M=X, k=2.4 (n=10), s=standard dev.
Uniformity requirements of pharmacopoeia met by direct compressible
formulation.
19. Sustained release dosage forms are intended to release the drug in desired concentrations for a prolonged
period of time. Therefore, they must contain larger amounts of the drug than single-dose formulations.
Dose dumping is defined as
‟unintended, rapid drug release in a short period of time of the entire amount or a significant fraction of the
drug contained in a modified release dosage form“.*
Dose dumping
Ensuring Safety and Consistency
Webinar - PVA for sustained release | 20.08.202019
tampering
grinding/crushing
dose division
pH / food effect dissolved in or taken
with alcoholic beverages
The dose dumping risk needs to be overcome to ensure patient safety and therapeutic
effect *definition based on EMA draft guideline EMA/CPMP/EWP/280/96 Corr1 and Meyer, R. J. and A. S.
Hussain (2005). Awareness Topic: Mitigating the Risks of Ethanol Induced Dose Dumping from Oral
Sustained/Controlled Release Dosage Forms. FDA’s ACPS Meeting, U.S. Department of Health and
Human Services, Food and Drug Administration.
20. Webinar - PVA for sustained release | 20.08.202020
Different media
Dose Dumping
Robust
performance at
different pH
values, no dose
dumping
Dissolution procedure:
USP Apparatus 2 (Paddle Apparatus),
900 mL phosphate buffer pH 6.8 / HCl 0.1 M, 50 rpm, 37 °C; n=3
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12 14 16 18 20 22
%ofPropranololHCldissolved
Time [h]
20 kN, PP pH 6.8 pH 6.8 20 kN, HCl 0.1 M
29. Simple process only requiring
mixing step(s) – stable,
homogeneous mixture is a
prerequsite
Compressibility and dissolution
performance confirmed with
various model drugs
Process comprises several
steps – granulation and mixing
– no liquid is applied
‟Pre“-compaction possibly
affects compressibility,
impact on dissolution not
expected
Complex process using liquid
– stable API mixtures are
achieved, compressibility could
be improved
Performance of PVA 40-88
challenging, specific process
beneficial?
Granulation
Application of different technologies
Direct compression Dry granulation Wet granulation
Webinar - PVA for sustained release | 20.08.202029
30. Application of different technologies
Dry Granulation
Webinar - PVA for sustained release | 20.08.202030
Components
Amount
mg/tablet %
Internal phase
Parteck® SRP 80 335 67
Model drug (Ascorbic
acid)
160 32
External phase
SiO2 highly dispersed 2.5 0.5
Parteck® LUB MST 2.5 0.5
• Roller compactor RCC 100x20, powtec Maschinen und Engineering GmbH,
Remscheid, Germany
• Smooth roller surface, roller speed 3 rpm, compaction pressure adjusted by
screw speed and roller gap; resulting compaction pressure 75 bar
• Integrated 1.25mm oscillating sieve with 50 rpm, 75 bar
31. Application of different technologies
Peformance in Dry Granulation
Webinar - PVA for sustained release | 20.08.202031
Tablet hardness acceptable, in comparison to DC process reduced.
Dissolution performance comparable to DC tablets.
207
121
0
50
100
150
200
250
300
20
Tablethardness[N]
Compression force [kN]
SRP80, DC SRP80, RC 75 bar
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12
Dissolution[%]
Time [h]
SRP80, DC SRP80, RC 75 bar
900 mL, Phosphatpuffer pH 2,7 (Titriplex III), 37°C, 50rpm
32. 5/10/20/30% water
139 rpm
0.5 kg batches
10/30/50% water
150 rpm
2 kg batches
10 % water/25% PVA 40-88
solution (4%)
Temperature 70 °C
1 kg batches
Wet Granulation
Application of different technologies
Low shear (LS) High shear (HS) Fluidized bed (FB)
Webinar - PVA for sustained release | 20.08.202032
Physical mixture of PVA 40-88 (74.75%) and model drug (Ascorbic acid, 25.25%)
prepared, granulation solution added.
MST/SiO2 (0.5 % each) added to final tableting mixture.
33. Application of different technologies
Performance of Wet Granulation Process
Webinar - PVA for sustained release | 20.08.202033
The granulation process is challenging due to the stickiness of the product.
Granules
Before drying
After drying/sieving
High shear Fluidized bed
37. Adressing main challenges
Parteck® SRP 80 for Sustained Release
Webinar - PVA for sustained release | 20.08.202037
1
Robust release performance – No dose dumping
- over a broad range of compression forces
- at different pH
- in presence of alcohol
2
3
4
5
Batch-to-batch consistency – Fully synthetic and chemically-defined product
Process cost efficiency – designed for direct compression being most efficient process.
Application in dry granulation as alternative process.
API dependent release kinetics – Sustained release performance confirmed for many
different APIs
Flexible modification of release profile – Achieved by modifying the formulation composition,
e.g. adding mannitol